Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · page 24 of 56
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.
Pitch deck · why_now · argue_timing · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 chart 1/1 list 1/1 paragraph 1/1 source-note 1/1 title 1/1
Components 6
primary bar-vertical bullet paragraph source-note headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.